Antonio Vinci, Fabio Ingravalle, Dorian Bardhi, Nicola Cesaro, Sara Frassino, Francesca Licata and Marco Valvano
September 29, 2022
cannabinoid supplementation as adjuvant therapy may increase the chances of success for standard therapy of Crohn’s Disease during the induction period; no statement on its potential usage during maintenance period can be derived from retrieved evidence. Its usage in Ulcerative Colitis is not to be recommended. If ever, low-dose treatment may be more effective than higher dosage. Mean CDAI reduction was found stronger in patients treated with cannabinoids (mean CDAI reduction = 36.63, CI 95% 12.27–61.19) than placebo. In future studies, it is advisable to include disease activity levels, as well as patient-level information such as genetic and behavioral patterns.
Vinci, A., Ingravalle, F., Bardhi, D., Cesaro, N., Frassino, S., Licata, F., & Valvano, M. (2022). Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biomedicines, 10(10), 2439.